+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sarepta Therapeutics - logo

Sarepta Therapeutics is a biopharmaceutical company that focuses on the development of RNA-based therapeutics for the treatment of rare neuromuscular diseases. The company offers EXONDYS 51, a disease-modifying therapy for the treatment of duchenne muscular dystrophy (DMD). It also develops SRP-4045 and SRP-4053, which are exon skipping clinical product candidates for the treatment of DMD. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.

From
Duchenne Muscular Dystrophy - Global Clinical Trials Review, H2, 2021 - Product Thumbnail Image

Duchenne Muscular Dystrophy - Global Clinical Trials Review, H2, 2021

  • Clinical Trials
  • November 2021
  • 223 Pages
From
mRNA: Therapeutics and Global Markets 2021-2026 - Product Thumbnail Image

mRNA: Therapeutics and Global Markets 2021-2026

  • Report
  • September 2021
  • 271 Pages
From
Dystrophin (DMD) - Pipeline Review, H2 2019 - Product Thumbnail Image

Dystrophin (DMD) - Pipeline Review, H2 2019

  • Drug Pipelines
  • December 2019
  • 117 Pages
From
Muscular Dystrophy Disease - Global Clinical Trials Review, H2, 2020 - Product Thumbnail Image

Muscular Dystrophy Disease - Global Clinical Trials Review, H2, 2020

  • Clinical Trials
  • November 2020
  • 113 Pages
From
From
From
From
From
From
From
From
Loading Indicator